INTRODUCTION
HEART FAILURE (HF) AFFECTS six million patients in the United States. 1 Although there has been some reduction in the HF admission rate and mortality in the last 10 years, the prognosis and burden of HF remains unacceptably high. New therapies are needed, which is the rationale for considering new approaches such as gene transfer.
Although many preclinical studies have shown benefits of gene transfer in animal models of HF, few have been translated to randomized clinical trials. The attraction of gene transfer is its simplicity-a one-time administration offers the possibility of safely providing benefits beyond standard pharmacological and device therapy in this devastating disease with high morbidity and mortality.
Gene transfer to improve the function of the failing heart in patients with HF with reduced ejection fraction (HFrEF) has now been performed in four randomized, placebo-controlled clinical trials. Three strategies have been employed: (1) intracoronary (IC) delivery of adeno-associated virus type 1 encoding sarcoplasmic reticulum Ca2+-ATPase (AAV1 .SERCA2a); (2) endocardial injection of a plasmid encoding stromal cell-derived factor-1 (pSDF-1); and (3) IC delivery of adenovirus-5 encoding adenylyl cyclase type 6 (Ad5.hAC6). These approaches, used in four randomized clinical trials, are the focus of this review.
METHODS
PubMed and ClinicalTrials.gov (without language restrictions) were searched for clinical trials published between January 1990 and October 2016, using the search terms ''gene transfer'' (and ''gene therapy'') and ''heart failure'' and related terms. Only four randomized clinical trials testing gene transfer in patients with HF were found, confirming that gene transfer for clinical HF is in its infancy. These four trials are summarized by providing the rationale for transgene selection, important preclinical or nonrandomized clinical trials, safety, and results. Finally, the results of the studies are summarized and perspectives are provided for future work in this area.
RESULTS AND DISCUSSION
The CUPID 2 and CUPID-2 3 trials used IC delivery of AAV1.SERCA2a. SERCA2a is a cardiac Ca2+ regulating protein. CUPID-2 used simultaneous intravenous infusion of nitroglycerine during IC vector delivery. The STOP-HF 4 clinical trial used endocardial injection of pSDF-1 to promote stem-cell recruitment and tissue repair, including angiogenesis in patients with HFrEF of ischemic etiology. Finally, a fourth randomized clinical trial used IC delivery of an adenovirus-5 vector encoding adenylyl cyclase 6 (Ad5.hAC6). 5 The AC6 gene transfer trial used simultaneous IC infusion of sodium nitroprusside during IC vector delivery (Table 1) .
CUPID and CUPID-2 (AAV1.SERCA2a)
Preliminary preclinical and non-randomized clinical studies. SERCA2a is a Ca2+ regulating protein on cardiac myocytes. Isolated cardiac myocytes from patients with HF have reduced expression and activity of SERCA2a and reduced shortening, abnormalities that are rectified by SERCA2a gene transfer. 6 Intracoronary delivery of AAV1.SERCA2a (10 12 DNAase resistant particles, drp) in pigs with volume overload was beneficial and was associated with increased cardiac SERCA2a expression. 7 In an initial open-label clinical trial (not randomized), nine subjects with stable symptomatic HFrEF (EF £30%) received IC AAV1.SER- CA2a (1.4 · 10 11 , 6 · 10 11 , or · 10 12 drp). Follow-up for 12 months after infusion showed no serious adverse events and evidence of improvement in symptoms, exercise, left ventricular (LV) function, and biomarkers. 8 These data were the basis for two subsequent randomized clinical trials.
CUPID
The CUPID trial 2 was a Phase 2 blinded, randomized, placebo-controlled, multicenter study examining the effects of AAV1.SERCA2a in 39 subjects with stable symptomatic HFrEF (EF £35%), maximal oxygen consumption £20 mL/kg/min, and an implantable cardioverter defibrillator (ICD). Fourteen participants received IC placebo, and 25 received IC AAV1.SERCA2a, at doses of 6 · 10 11 (n = 8), 3 · 10 12 (n = 8), or 3 · 10 13 (n = 9) drp. Subjects were screened to exclude those with detectable neutralizing antibodies against AAV1. The trial used five efficacy domains: symptoms, functional (6 min walk distance and peak oxygen consumption), biomarker, LV volume and ejection fraction, and clinical outcomes, which included seven different endpoints.
Safety in CUPID. IC AAV1.SERCA2a was well tolerated, with no untoward effects attributed to the vector or transgene 1 year later. The incidence of serious and non-serious adverse events was highest in the subjects who received placebo and lowest in those who received the highest dose of AAV1.SERCA2a. There was no evidence of cellular immune response to the vector. There were eight deaths: four in the placebo group, three in the lowdose, one in the mid-dose, and none in the highdose groups. The differences in mortality were not significant ( Table 2) .
Efficacy in CUPID. The 6 month primary endpoint was achieved in all three of the pre-specified analyses for the AAV1.SERCA2a high-dose group, including the group-level analysis in functional (6MWT, p = 0.14) and LV function/remodeling (Endsystolic volume [ESV], p = 0.057) domains, the individual-level analysis ( p = 0.052), and the outcome endpoint (using duration of cardiovascular hospitalizations, p = 0.08). The clinical event rate in all three AAV1.SERCA2a groups was delayed or reduced compared with placebo subjects. The hazard ratios (HR) at 12 months for recurrent clinical events (adjusted for correlated terminal events) for the low-, mid-, and high-dose AAV1.SERCA2a groups versus placebo were 0.40 ( p = 0.11), 0.44 ( p = 0.12), and 0.12 ( p = 0.003), respectively ( Table 2) .
CUPID 2
The CUPID-2 study 3 was a Phase 2b randomized, double blind, multicenter study that enrolled pa- tients with stable symptomatic HFrEF (EF £35%) ( Table 1) . Randomized patients had 50% nonischemic etiology, and 77% had an ICD. Patients were randomized 1:1 to receive IC infusion of placebo (n = 122) or AAV1.SERCA2a (n = 121) at a dose of 10 13 drp. The study product was delivered in proportion to myocardium perfused, targeting two-thirds of the dose to the anterolateral wall, and intravenous nitroglycerin was infused during test article delivery. The primary efficacy endpoint was time to recurrent events, defined as hospital admission because of HF or ambulatory treatment for worsening HF. After observing a lower event rate than anticipated in the first 101 patients, additional inclusion criteria of elevated N-terminal pro-B-type natriuretic peptide (NT-proBNP) or a recent HF-related hospital admission were added to the protocol.
Safety in CUPID-2. No group differences in serious adverse events were seen. There were 262 clinical events in the placebo group and 190 events in the AAV1.SERCA2a group, most of which were admission to hospital. Death occurred in 16% of subjects in the placebo group (18/20 deaths were of cardiovascular origin) and in 21% of the subjects in the AAV1.SERCA2a group (22/25 deaths were of cardiovascular origin) ( Table 2 ).
Efficacy in CUPID-2. Patients were followed for at least 12 months after randomization (median 18 months). AAV1.SERCA2a did not improve time to recurrent events compared to placebo (104 vs. 128 events; HR = 0.93, p = 0.81). There were 104 recurrent and 36 terminal events reported in the AAV1.SERCA2a group compared to 128 recurrent and 29 terminal events in the placebo group. Most of the recurrent events were admission to hospital because of HF. There were no group differences in the primary endpoint or any of the secondary or exploratory efficacy endpoints (change in NYHA class, 6 min walk distance, symptoms, or NT-proBNP level). Nonstandard statistical methods were used for the CUPID study, and this may have contributed to the disparity in results between CUPID and CUPID 2 ( Table 2) .
STOP-HF
Preliminary preclinical and nonrandomized clinical studies. SDF-1 is a factor that activates endogenous stem cells, which facilitates tissue repair particularly through vasculogenesis. 9, 10 The authors rationale was to use gene transfer of a DNA plasmid encoding human SDF-1 (pSDF-1) to increase tissue repair pathways including myocardial vasculogenesis and thereby improve function of the failing ischemic heart. Indeed, their group had shown in a pig HF model that endocardial injection of pSDF-1 increased cardiac function and vasculogenesis 90 days after delivery. 10 This strategy differs from the others reviewed in three ways. First, SDF-1, unlike SERCA2a and AC6, is a cytokine that has no direct effects on cardiac function, but operates via stimulating endogenous repair processes including angiogenesis. Second, a plasmid vector rather than a virus vector is used. Third, delivery is by direct injection into the heart rather than by IC delivery.
In an initial nonrandomized, open-label clinical trial, 11 17 subjects with symptomatic ischemiabased HFrEF (EF < 40%) and an ICD received one of three doses (5, 15, or 30 mg) of pSDF-1 delivered via endocardial catheter-based injection (15 injections of equally divided amounts of pSDF-1 per patient). There was no placebo control in this initial trial, but improvements in 6 min walk distance and symptoms were seen in the groups that received 15 mg (n = 6) and 30 mg (n = 7) of pSDF-1. There were some procedure-related adverse events that were deemed to be at an acceptably low rate.
The STOP-HF trial 4 was a Phase 2 blinded, placebo-controlled, multicenter study in which 93 subjects with ischemic etiology stable symptomatic HFrEF (EF < 40%) and an ICD were randomized 1:1:1 to receive endocardial catheter-based injection of placebo or 15 or 30 mg of pSDF-1 ( Table 1 ). The primary endpoint was a composite of symptoms (Minnesota Living with Heart Failure Questionnaire) and 6 min walk distance evaluated before and 4 months after randomization. Echocardiography was used to assess LV dimensions and function, which were secondary endpoints. Enrollees had a mean EF of 28 -7%, and were 11 -9 months out from myocardial infarction.
Safety in STOP-HF. There were no productrelated unanticipated serious adverse events among the 62 patients randomized to receive pSDF-1 ( Table 2) .
Efficacy in STOP-HF. The primary endpoint of the trial was not met ( p = 0.89), as the composite score of the 6 min walk distance and symptoms was increased in both placebo and treated cohorts 4 months after randomization. However, a prespecified analysis indicated that patients with the lowest tertile of EF who received the higher dose of pSDF-1 (30 mg) showed a 7% unit increase in EF compared with a 4% unit decrease in EF among placebo patients at 12 months ( p = 0.01). The authors concluded that although the primary end-point was not met, endocardial injection of pSDF-1 was safe and possibly effective in patients with the lowest EF, which may be the target population in subsequent trials (Table 2) .
AC6 gene transfer trial
AC6 is a large (130 kD) protein that catalyzes the conversion of adenosine triphosphate (ATP) to cyclic adenosine monophosphate (cAMP). Myocardial cAMP levels are an important element in heart function. In studies conducted in pigs with HF, IC AC6 gene transfer increased LV AC6 content, improved heart function, and reversed adverse LV remodeling. 12 The benefits of AC6 appear to be independent of increased levels of cAMP through favorable actions on Ca2+ handling. 13, 14 These novel properties of AC6 differ from drugs that increase intracellular cAMP, such as milrinone, which reduce survival in HF. Indeed, increased cardiac AC6 content prolongs life in murine genetic cardiomyopathy. 15 Finally, unlike milrinone, in preclinical studies, AC6 does not cause unbridled cAMP generation and reduces arrhythmias. 16 The trial examined the safety and efficacy of IC delivery of Ad5.hAC6 in patients with symptomatic HFrEF (EF £40%). This multicenter, double-blind, placebo-controlled, Phase 2 study 5 randomized 56 subjects at a 3:1 ratio to receive IC Ad5.hAC6 at one of five doses, ranging from 3.2 · 10 9 to 10 12 virus particles (vp) or placebo, along with concomitant infusion of IC nitroprusside ( Table 1 ). The primary endpoints were change from baseline in treadmill exercise time in rest or dobutamine-stimulated EF by echocardiography and in LV pressure development (+dP/dt) or decline (-dP/dt) before and during dobutamine infusion during cardiac catheterization. Follow-up measurement of dP/dt was at 4 weeks; exercise testing and EF were reassessed 4 and 12 weeks after randomization. Pre-specified analyses included a key efficacy comparison on an intentionto-treat basis of the 14 placebo participants, with the 24 Ad5.hAC6 participants receiving the highest two doses (D4 + D5).
Data were reported for 56 subjects who were randomized and monitored for up to 1 year. The 42 (75%) subjects who received Ad5.hAC6 were well matched with the 14 (25%) who received placebo. Approximately half of each group had an ischemic etiology of HF.
Safety in AC6 gene transfer trial. No significant adverse events occurred during study product administration. Transient troponin I elevations (with normal CKMB and no chest pain or ECG changes) occurred the following day, leading to 1 day hospitalization in three participants, one of whom received placebo. Troponin I was increased compared with baseline levels on days 2 and 4 in both the placebo and D4 + D5 participants, with no group differences and no increases in creatine kinase MB. There was no evidence for hepatotoxicity in patients receiving Ad5.hAC6.
At 12 months, the percentage of participants with one or more serious adverse events was similar between groups. The HF admission rate was 9.5% (four episodes among 42 subjects) among the AC6 participants and 28.6% (four episodes among 14 subjects) among placebo participants ( p < 0.10). There were two deaths, one in each group: (AC6, 2%; placebo, 7%; p = 0.40). There were two transplantations, both in AC6 participants ( p = 0.9 vs. placebo). The overall rates of ICD events and episodes of non-sustained ventricular tachycardia showed no group differences (Table 2) .
Efficacy in AC6 gene transfer trial. Twenty-one subjects who received the highest two doses of Ad5.hAC6 (D4 + D5) had a significant increase in EF at 4 weeks (29.7-36.3%, mean increase of 6.0 EF units; p < 0.004) but not at 12 weeks (29.7-34.2%, mean increase of 3.0 EF units; p = 0.16). The increase in EF at 4 weeks in AC6 participants was dose related ( p < 0.04). The 14 subjects who received placebo had an increase from baseline EF that was not statistically significant at 4 weeks (29.6-33.7%, mean increase of 4.1 EF units; p = 0.08) or at 12 weeks (29.6-31.6%, mean increase of 0.8 EF units; p = 0.31).
Treadmill performance did not increase in the 17 D4 + D5 participants who were able to exercise at 4 weeks or in the 13 placebo participants (from 416 to 446 s; p = 0.46). Treadmill time increased to 501 s at 12 weeks in both groups, which was a significant change from baseline in the 12 placebo subjects ( p = 0.03) but not in the 17 D4 + D5 subjects ( p = 0.06).
Basal (unstimulated) LV peak -dP/dt at 4 weeks improved in 21 D4 + D5 subjects (-39 mmHg/s) but worsened after randomization in placebo subjects (+93 mmHg/s change), and this betweengroup difference was significant ( p < 0.03). There was no group difference in dobutamine-stimulated LV peak +dP/dt or LV peak -dP/dt.
Neither group had a change in HF symptom score at 4 weeks. At 12 weeks, there was a reduction in symptom score in D4 + D5 participants (from 28.8 to 20.5; p = 0.0005) but not in placebo participants (from 30.8 to 23; p = 0.16). Anti-Ad5 titers ranged from <1:18 (undetectable) to >1:4,608. There was no asso-ciation between pre-randomization anti-Ad5 titer and any efficacy endpoint ( Table 2 ).
The investigators concluded that this one-time administration of Ad5.hAC6 safely increased LV function beyond standard HF therapy and that larger trials were warranted.
Safety of clinical gene transfer in HFrEF
In each of these trials, gene transfer was performed with an acceptable safety profile ( Table  2 ). The delivery technique was not associated with an increased rate of adverse events. Subjects had an uneventful subsequent early course, with only low levels of troponin-I elevation without clinical sequalae noted in both the placebo and Ad5.hAC6 subjects in the AC6 trial. There was no evidence of adverse consequences of gene transfer at 1 year follow-up in CUPID-2, STOP-HF, and Ad5.hAC6.
The genes delivered in these trials were anticipated to improve the function of the failing heart in different ways. To promote the extent of IC vector delivery and thereby reduce vector dose, simultaneous intravenous nitroglycerine 17 or IC nitroprusside 18 were used. Arrhythmias were a theoretical concern, and in these trials most of the subjects had an ICD in place. However, there was no increase in arrhythmias seen in the subjects who received gene transfer in these trials, in particular there was no increase in arrhythmic clinical events compared with subjects who received placebo ( Table 2) .
The safety profile of clinical gene transfer in this high-risk patient population is a major finding. Recognizing the early and mixed results in terms of efficacy in these studies, safety supports further investigations using gene transfer.
CONCLUSIONS
The favorable safety profile seen now in four randomized clinical trials of gene transfer in patients with HFrEF has paved the way for further progress in this field. Although the experience with these agents is limited, clinically evident adverse immunologic responses, arrhythmias, and other adverse events have not been as high as anticipated. The clinical course of subjects receiving gene transfer has been as good as or better than that of subjects receiving placebo. Remaining challenges include refinement of endpoints, optimal dosing, selection of transgene, and the persistence of benefits.
The promising potential efficacy of AAV1 .SERCA2a seen in the initial CUPID was not borne out by the larger CUPID 2 study. The STOP-HF study showed potential benefits in patients with the lowest EF, and additional trials may be planned. The current work with Ad5.hAC6 has shown potential benefit at higher doses. A larger study will be required to confirm the preliminary indications of improvement in EF and the reduction of clinical adverse events.
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